Thermo Fisher Scientific Inc. (NYSE:TMO) is Investidor Profissional Gestao de Recursos Ltda.'s 6th Largest Position

Key Points

• Investidor Profissional Gestao de Recursos Ltda. increased its stake in Thermo Fisher Scientific Inc. by 40.3% during the first quarter, holding shares valued at approximately $7.29 million.
• Multiple institutional investors have recently purchased shares of Thermo Fisher, with 89.23% of the company's stock owned by institutional investors.
• Thermo Fisher Scientific reported earnings of $5.36 per share for the last quarter, exceeding estimates and generating revenue of $10.86 billion.

Investidor Profissional Gestao de Recursos Ltda. lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 40.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,648 shares of the medical research company's stock after buying an additional 4,210 shares during the period. Thermo Fisher Scientific makes up about 4.7% of Investidor Profissional Gestao de Recursos Ltda.'s investment portfolio, making the stock its 6th largest holding. Investidor Profissional Gestao de Recursos Ltda.'s holdings in Thermo Fisher Scientific were worth $7,289,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC raised its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its stake in Thermo Fisher Scientific by 0.3% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after acquiring an additional 461 shares during the last quarter. Trek Financial LLC grew its position in Thermo Fisher Scientific by 49.4% in the fourth quarter. Trek Financial LLC now owns 1,734 shares of the medical research company's stock worth $902,000 after acquiring an additional 573 shares in the last quarter. Finally, Ritter Daniher Financial Advisory LLC DE raised its holdings in shares of Thermo Fisher Scientific by 35.1% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 150 shares of the medical research company's stock valued at $78,000 after purchasing an additional 39 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 1.4%

NYSE TMO traded up $6.15 during mid-day trading on Thursday, hitting $455.09. The company's stock had a trading volume of 1,490,140 shares, compared to its average volume of 3,299,804. The firm has a market capitalization of $171.85 billion, a price-to-earnings ratio of 26.32, a PEG ratio of 2.40 and a beta of 0.74. The company's 50 day simple moving average is $425.62 and its 200 day simple moving average is $464.94. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the company earned $5.37 earnings per share. The company's revenue for the quarter was up 2.9% on a year-over-year basis. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 8,000 shares of the company's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total value of $3,635,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at approximately $52,340,824.30. This represents a 6.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,400 shares of company stock worth $8,345,792. Company insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on TMO shares. Evercore ISI lowered their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. HSBC reissued a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Royal Bank Of Canada reduced their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Finally, Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.